Abstract:Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to numerous structurally and functionally different chemotherapeutic agents. MDR is considered one of the principal reasons for the failure of many forms of clinical chemotherapy. Several factors are involved in the development of MDR including increased expression of efflux transporters, the tumor microenvironment, changes in molecular targets and the activity of cancer stem cells. Recently, researchers have designed and developed a number of small molecule inhibitors and derivatives of natural compounds to overcome various mechanisms of clinical MDR. Unfortunately, most of the chemosensitizing approaches have failed in clinical trials due to non-specific interactions and adverse side effects at pharmacologically effective concentrations. Nanomedicine approaches provide an efficient drug delivery platform to overcome the limitations of conventional chemotherapy and improve therapeutic effectiveness. Multifunctional nanomaterials have been found to facilitate drug delivery by improving bioavailability and pharmacokinetics, enhancing the therapeutic efficacy of chemotherapeutic drugs to overcome MDR. In this review article, we discuss the major factors contributing to MDR and the limitations of existing chemotherapy- and nanocarrier-based drug delivery systems to overcome clinical MDR mechanisms. We critically review recent nanotechnology-based approaches to combat tumor heterogeneity, drug efflux mechanisms, DNA repair and apoptotic machineries to overcome clinical MDR. Recent successful therapies of this nature include liposomal nanoformulations, cRGDY-PEG-Cy5.5-Carbon dots and Cds/ZnS core-shell quantum dots that have been employed for the effective treatment of various cancer sub-types including small cell lung, head and neck and breast cancers.

A review on phytochemicals as combating weapon for multidrug resistance in cancer

Phytochemicals as weapons against drug resistance

Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review

The mechanisms of multidrug resistance of breast cancer and research progress on related reversal agents

Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges

Overcoming multiple drug resistance in cancer using polymeric micelles

Modulation of Multidrug Resistance Transporters by Food Components and Dietary Supplements: Implications for Cancer Therapy Efficacy and Safety

Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein

Tackling Multiple-Drug-Resistant Bacteria With Conventional and Complex Phytochemicals

The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy

Resveratrol: an Overview of Its Anti-Cancer Mechanisms

Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons

Drug-metabolizing enzymes: role in drug resistance in cancer

Advances in Nanobiotechnology-Propelled Multidrug Resistance Circumvention of Cancer

The Role of P-Glycoprotein (P-gp) in Cancer Multidrug Resistance (MDR): Challenges for Inhibiting P-gp in the Context of Overcoming MDR

Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.

Drug resistance in cancer: mechanisms and tackling strategies

Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Mechanisms of Multidrug Resistance in Cancer Chemotherapy